<DOC>
	<DOCNO>NCT00863538</DOCNO>
	<brief_summary>To evaluate efficacy , safety pharmacokinetics profile KPS-0373 patient SCD</brief_summary>
	<brief_title>Phase II Study KPS-0373 Patients With Spinocerebellar Degeneration ( SCD )</brief_title>
	<detailed_description />
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Thyrotropin-Releasing Hormone</mesh_term>
	<criteria>SCD mild moderate ataxia Patients secondary ataxia Patients clinically significant hepatic , renal , cardiovascular dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Spinocerebellar degeneration</keyword>
	<keyword>Thyrotropin-Releasing Hormone ( TRH )</keyword>
	<keyword>SCD</keyword>
</DOC>